<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie R Park, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Burkitt lymphoma (BL) is a highly aggressive B cell non-Hodgkin lymphoma characterized by the translocation and deregulation of the <em>MYC</em> gene on chromosome 8. Three distinct clinical forms of BL are recognized: endemic (African), sporadic (nonendemic), and immunodeficiency associated. Although they are histologically identical and have similar clinical behavior, there are differences in epidemiology, clinical presentation, and genetic features between the three forms, as described below.</p><p>BL and Burkitt leukemia are considered different manifestations of the same disease in the World Health Organization 5<sup>th</sup> edition (WHO5) of the classification of hematolymphoid tumors [<a href="#rid1">1</a>] and the International Consensus Classification (ICC) of mature lymphoid neoplasms [<a href="#rid2">2</a>]. Both classification systems also recognize three aggressive B cell lymphoma entities that resemble BL: "Burkitt-like lymphoma with 11q aberration," "High-grade B cell lymphoma with <em>MYC</em> and <em>BCL2</em> rearrangements," and "High-grade B cell lymphoma, not otherwise specified" [<a href="#rid1">1,2</a>]. Some tumors in this group were previously classified as "Burkitt-like" lymphoma [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p>The epidemiology, clinical features, pathology, and diagnosis of BL will be reviewed here. The pathobiology and treatment of BL are discussed separately, as is a general approach to the diagnosis, staging, and prognosis of the lymphomas. (See  <a class="medical medical_review" href="/z/d/html/4723.html" rel="external">"Pathobiology of Burkitt lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4734.html" rel="external">"Treatment of Burkitt leukemia/lymphoma in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4696.html" rel="external">"Pretreatment evaluation and staging of non-Hodgkin lymphomas"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The exact worldwide incidence of BL is not known, as collection of these types of epidemiologic data is limited by a lack of resources that are needed for case ascertainment and accurate diagnosis in the resource-limited countries that have the highest apparent incidence (eg, equatorial Africa) [<a href="#rid4">4</a>]. For epidemiologic and diagnostic purposes, cases of BL are generally divided into three distinct clinical forms: endemic (African), sporadic (nonendemic), and immunodeficiency associated. The endemic and sporadic clinical variants of BL differ geographically.</p><p class="bulletIndent1"><span class="glyph">●</span>Endemic – The endemic variant is found in equatorial Africa and New Guinea. The incidence of BL in Africa is approximately 50-fold higher than in the United States [<a href="#rid5">5</a>]. BL accounts for 30 to 50 percent of all childhood cancer in equatorial Africa with an estimated incidence of 3 to 6 cases per 100,000 children per year [<a href="#rid4">4</a>]. The peak incidence occurs in children aged four to seven years, and the male:female ratio is approximately 2:1.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sporadic – The sporadic variant is seen in the United States and Western Europe. BL comprises 30 percent of pediatric lymphomas and &lt;1 percent of adult non-Hodgkin lymphomas in the United States [<a href="#rid6">6</a>]. This translates into an estimated incidence of approximately three cases per million persons per year in both children and adults. In Europe, the incidence is approximately 2.2 cases per million persons per year [<a href="#rid7">7</a>]. The peak incidence occurs in children aged 11 years. Among adults, sporadic BL is typically seen in patients less than 35 years of age, with a median age at diagnosis of 30 years [<a href="#rid3">3,8</a>]. Sporadic BL is more common among White Americans compared with African Americans or Asian Americans [<a href="#rid6">6</a>]. Data suggest that it may be substantially more common in some areas of Central America (eg, Guatemala) [<a href="#rid9">9</a>]. In all groups, the majority of patients are male with a 3 or 4:1 male:female ratio [<a href="#rid6">6,10,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">"Clinical manifestations and treatment of Epstein-Barr virus infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunodeficiency associated – The immunodeficiency-associated variant is primarily seen in persons with human immunodeficiency virus (HIV) infection and less commonly in patients with other causes of immunodeficiency (eg, recipients of organ transplants). In HIV-positive patients, BL typically affects those with a relatively high CD4 count (eg, &gt;200 cells/microL) and no opportunistic infections [<a href="#rid12">12</a>]. In comparison to the majority of other HIV-associated lymphomas, the rate of BL in the HIV-positive population has not decreased with the advent of potent antiretroviral therapy (ART). This is presented in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4726.html" rel="external">"HIV-related lymphomas: Epidemiology, risk factors, and pathobiology"</a>.)</p><p></p><p class="headingAnchor" id="H7524115"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>BL is derived from germinal center B cells. The development of BL is dependent on the constitutive expression of the <em>MYC</em> proto-oncogene located at chromosome 8q24, which encodes the MYC protein transcription factor. This transcription factor modulates the expression of target genes that regulate many cell processes including cell growth and division, immortalization, Warburg metabolism, and cell death by apoptosis. (See  <a class="medical medical_review" href="/z/d/html/4723.html" rel="external">"Pathobiology of Burkitt lymphoma"</a>.)</p><p>The <em>MYC</em> chromosomal translocation that characterizes BL has the molecular signature of a recombination error that occurs during the attempted diversification of immunoglobulin (Ig) gene segments in B cells. Chromosomal translocations involve nonhomologous joining of the ends of deoxyribonucleic acid (DNA) breaks that occur in at least two different places in the genome simultaneously. Sequencing of the genomic sequences where <em>MYC</em> is joined to Ig loci in BL indicates that the DNA breaks in the involved Ig genes occur through processes that are normal for B cells, namely either attempted somatic hypermutation of variable segment genes or Ig class switch recombination. Some reports suggest that DNA breaks near <em>MYC</em> result from the recruitment of activation-induced cytosine deaminase (AID), an enzyme required for Ig class switching, to enhancer sites adjacent to the <em>MYC</em> gene body that are characterized by overlapping sense and antisense (convergent) transcription [<a href="#rid13">13,14</a>]. It is not known how the DNA breaks in <em>MYC</em> come to be spatially close to DNA breaks in the Ig locus in the interphase nucleus, which is a prerequisite for these DNA ends to be joined to form <em>MYC</em> translocations. The resulting dysregulation of <em>MYC</em> is complemented by additional mutations in oncogenes and tumor suppressors (described below); the basis for the genesis of these mutations is largely unknown.</p><p>Chronic Epstein-Barr virus (EBV) infection appears to play a role in virtually all cases of endemic (African) BL and in a minority of cases of sporadic and immunodeficiency-associated BL. Work in mouse models suggests that malaria selectively induces B cell lymphomas with chromosomal translocations involving <em>MYC</em> by causing protracted AID expression in germinal center B cells [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/4726.html" rel="external">"HIV-related lymphomas: Epidemiology, risk factors, and pathobiology"</a> and  <a class="medical medical_review" href="/z/d/html/4750.html" rel="external">"HIV-related lymphomas: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Patients with BL present with rapidly growing tumor masses and often have evidence of spontaneous tumor lysis with a very high serum lactate dehydrogenase (LDH) concentration and elevated uric acid levels. The tumor doubling time is very short (eg, 25 hours). </p><p>Three distinct clinical forms of BL are recognized: endemic, sporadic, and immunodeficiency associated [<a href="#rid16">16</a>]. Although they are histologically identical and have similar clinical behavior, there are differences in epidemiology, clinical presentation, and genetic features between the three forms  (<a class="graphic graphic_table graphicRef77710" href="/z/d/graphic/77710.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Endemic BL – The endemic (African) form presents as a jaw or facial bone tumor  (<a class="graphic graphic_picture graphicRef52625" href="/z/d/graphic/52625.html" rel="external">picture 1</a>) in 50 to 60 percent of cases. Primary involvement of the abdomen is less common. The primary tumor can spread to other extranodal sites, including mesentery, ovary, testis, kidney, breast, and meninges. Primary involvement of lymph nodes, mediastinum, and spleen are uncommon. Bone marrow involvement is seen in less than 10 percent of patients at the time of initial presentation but is a common complication of recurrent or treatment resistant disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonendemic (sporadic) BL – The nonendemic (sporadic) form usually has an abdominal presentation, most often with massive disease and ascites, involving the distal ileum, stomach  (<a class="graphic graphic_picture graphicRef69159" href="/z/d/graphic/69159.html" rel="external">picture 2</a>), cecum and/or mesentery, kidney, testis, ovary, breast, bone marrow, or central nervous system (CNS). Presenting symptoms can include those related to bowel obstruction or gastrointestinal bleeding, often mimicking acute appendicitis or intussusception. Approximately 25 percent of cases have involvement of the jaw or facial bones. Lymphadenopathy, if present, is generally localized. Bone marrow and CNS involvement occurs in approximately 30 and 15 percent of cases, respectively, at the time of initial presentation but are common complications of recurrent or treatment resistant disease [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunodeficiency-related BL – The presentation of patients with immunodeficiency-related BL is often accompanied by signs or symptoms related to the underlying immunodeficiency (eg, acquired immune deficiency syndrome [AIDS], congenital immunodeficiency, acquired immunodeficiency due to hematopoietic or solid organ transplantation). Immunodeficiency-related cases more often involve lymph nodes, bone marrow, and CNS. (See  <a class="medical medical_review" href="/z/d/html/4750.html" rel="external">"HIV-related lymphomas: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H5"><span class="h2">Morphology</span><span class="headingEndMark"> — </span>Biopsy of the tumor mass demonstrates effacement of the normal architecture by sheets of atypical lymphoid cells [<a href="#rid3">3</a>]. At low power, the tumor has a "moth-eaten" appearance, often with interspersed areas of coagulative necrosis or hemorrhage. There is an extremely high rate of proliferation as well as a high rate of apoptotic cell death. A classic "starry-sky" pattern is usually present, imparted by numerous benign macrophages (histiocytes) that have ingested apoptotic tumor cells (ie, tingible body macrophages)  (<a class="graphic graphic_picture graphicRef65094" href="/z/d/graphic/65094.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef52925" href="/z/d/graphic/52925.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef59619" href="/z/d/graphic/59619.html" rel="external">picture 5</a>). The benign histiocytes ("the stars") are large with abundant, clear cytoplasm and are dispersed relatively evenly throughout a background of basophilic tumor cells ("the sky").</p><p>At higher power, BL tumor cells classically are monomorphic, medium-sized cells with round nuclei, multiple dark nucleoli, and basophilic cytoplasm  (<a class="graphic graphic_picture graphicRef57366" href="/z/d/graphic/57366.html" rel="external">picture 6</a> and <a class="graphic graphic_picture graphicRef72438" href="/z/d/graphic/72438.html" rel="external">picture 7</a>) [<a href="#rid3">3</a>]. Cytologically, these cells resemble centroblasts within the dark zones of normal germinal centers of the secondary lymphoid follicle. Prominent cytoplasmic lipid vacuoles are usually evident on air-dried imprints or smears. The interspersed benign macrophages are large and irregularly shaped with abundant, clear cytoplasm, pale nuclei, and inconspicuous nucleoli.</p><p>The growth fraction of BL is very high, with frequent mitotic figures being seen and the fraction of Ki-67+ (MIB-1+) cells approaching 100 percent.</p><p>Several morphologic variants may be seen. Occasionally the tumor cells are associated with a marked granulomatous reaction, which may be so profound as to obscure the tumor cells lurking in the background. Another variant is marked by greater nuclear pleomorphism and more prominent nucleoli than are typical of "classic" forms of BL.</p><p class="headingAnchor" id="H6"><span class="h2">Immunophenotype</span><span class="headingEndMark"> — </span>The tumor cells express surface Ig of the IgM type and Ig light chains (kappa much more often than lambda), B cell-associated antigens (CD19, CD20, CD22, CD79a), germinal center-associated markers (CD10 and BCL6), as well as HLA-DR and MYC  (<a class="graphic graphic_picture graphicRef50088" href="/z/d/graphic/50088.html" rel="external">picture 8</a>) [<a href="#rid3">3</a>]. They lack expression of CD5 and B cell leukemia/lymphoma 2 (BCL2) and typically lack expression of CD23 and TdT. BCL6 protein staining is in a nuclear pattern and independent of <em>BCL6</em> gene rearrangement. </p><p>Expression of CD21, the Epstein-Barr virus (EBV)/C3d receptor, is dependent on EBV status of the tumors. Essentially all cases of endemic BL are EBV positive and express CD21, whereas the vast majority of nonendemic BL in nonimmunosuppressed patients are EBV negative and lack CD21 expression. EBV involvement in BL occurring in the setting of immunodeficiency falls between these two extremes. For example, 25 to 40 percent of BL occurring in HIV-positive patients are EBV associated, as are a high fraction of BL associated with organ transplantation. BL generally lacks the adhesion molecules LFA-1 (CD11a/CD18), p150/95 (CD11c), and CD44. (See  <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">"Clinical manifestations and treatment of Epstein-Barr virus infection"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Genetic features</span></p><p class="headingAnchor" id="H8"><span class="h3">Translocations involving the MYC oncogene</span><span class="headingEndMark"> — </span>In virtually all studies, BL is associated with a translocation between the long arm of chromosome 8, the site of the <em>MYC</em> oncogene (8q24), and one of three locations on Ig genes [<a href="#rid17">17-22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The Ig heavy chain gene on chromosome 14 (approximately 80 percent) – t(8;14)</p><p class="bulletIndent1"><span class="glyph">●</span>The kappa light chain gene on chromosome 2 (approximately 15 percent) – t(2;8)</p><p class="bulletIndent1"><span class="glyph">●</span>The lambda light chain gene on chromosome 22 (approximately 5 percent) – t(8;22)</p><p></p><p>In endemic cases, the breakpoint on chromosome 14 involves the heavy chain joining region, while in nonendemic cases, the translocation involves the heavy chain switch region [<a href="#rid18">18,23</a>]. In endemic cases, the breakpoint in chromosome 8 usually lies adjacent to the <em>MYC</em> gene, while in sporadic cases it often lies within intron 1 of <em>MYC</em>. (See  <a class="medical medical_review" href="/z/d/html/4723.html" rel="external">"Pathobiology of Burkitt lymphoma", section on 'MYC overexpression'</a>.)</p><p>Whole genome sequencing and ribonucleic acid (RNA) sequencing of 230 BLs from endemic and nonendemic regions showed that the few BLs without detectable cytogenetic rearrangements involving <em>MYC</em> typically have cryptic <em>MYC</em> rearrangements or small insertions near the <em>MYC</em> locus; thus, <em>MYC</em> aberrations are virtually ubiquitous in BL [<a href="#rid24">24</a>]. </p><p>Cases with "double-hit" translocations involving <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> are not considered variants of BL; such cases are variously classified as "high-grade B cell lymphoma with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> rearrangements" or high-grade B cell lymphoma, not otherwise specified [<a href="#rid1">1,2</a>]. Such tumors are more common in older adults, are more likely to have atypical <em>MYC</em> rearrangements involving genes other than IgH, and sometimes appear to stem from transformation of an underlying lower-grade B cell lymphoma, such as follicular lymphoma.</p><p class="headingAnchor" id="H9"><span class="h3">Other genetic abnormalities</span><span class="headingEndMark"> — </span>Ig heavy and light chain genes are rearranged. Studies of the Ig variable region genes show conflicting results: one study reported unmutated genes [<a href="#rid25">25</a>], while others report somatic mutations and intraclonal heterogeneity, consistent with ongoing mutations [<a href="#rid26">26-28</a>].</p><p>Mutations in the 5' noncoding region of the <em>BCL6</em> gene, similar to those seen in diffuse large B cell lymphoma, have been reported in 25 to 50 percent of BL [<a href="#rid29">29</a>]. Most African cases contain clonal EBV genomes, as do 25 to 40 percent of the cases associated with AIDS [<a href="#rid30">30</a>].</p><p>In a study involving 33 children and 37 adults with BL, in which all subjects had translocations involving chromosome 8, additional abnormalities were present in 81 and 73 percent of the children and adults, respectively [<a href="#rid31">31</a>]. The most commonly observed abnormalities involved chromosomes 1, 6, 13, 17, and 22. Of these, only abnormalities of chromosome 17 (the location of <em>TP53</em>) were poor prognostic features in adults.</p><p>The potential value of gene expression profiling (GEP) in diagnosing BL was illustrated in two large studies that identified a characteristic molecular signature that was able to differentiate BL from diffuse large B cell lymphoma [<a href="#rid32">32,33</a>]. While use of GEP has not found its way into clinical practice to establish the diagnosis of BL, new approaches that simplify the detection of RNA signature (eg, NanoString analysis, which has been proposed as a means for sub-classification of diffuse large B cell lymphoma [<a href="#rid34">34</a>]) may make use of GEP more attractive in the future.</p><p>Next-generation sequencing studies of BL have revealed that all three subtypes are frequently associated with mutations in the transcription factor TCF3 (also known as E2A, 10 to 25 percent of cases) or a negative regulator of TCF3, ID3 (35 to 58 percent of cases) [<a href="#rid35">35</a>]. Notably, the <em>ID3</em> mutations are loss-of-function mutations, whereas most <em>TCF3</em> mutations are gain-of-function mutations that abrogate ID3 binding to TCF3. Mutations in these genes are rare in diffuse large B cell lymphoma and other B cell lymphomas, suggesting that TCF3 gain of function is a defining lesion in BL. (See  <a class="medical medical_review" href="/z/d/html/4723.html" rel="external">"Pathobiology of Burkitt lymphoma", section on 'Other genetic lesions'</a>.)</p><p>A study of 230 BLs from endemic and nonendemic regions that included a large number of adult and pediatric cases used whole genome sequencing and RNA sequencing to identify molecular subtypes of BL [<a href="#rid24">24</a>]. This study suggests the existence of three distinct subtypes of BL defined by different patterns of somatic mutations in oncogenes and/or tumor suppressor genes. Each subtype also showed a distinct pattern of gene expression, and one of these subtypes, defined by enrichment for mutations in the genes <em>DDX3X</em>, <em>GNA13</em>, and <em>GNAI2</em>, was associated with EBV positivity and occurrence in the pediatric population. Additional work is needed to determine if these molecular subtypes are associated with distinct clinical outcomes.</p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>BL should be suspected in a patient with a rapidly growing tumor mass of the jaw, abdomen, or other sites. </p><p>The diagnosis of BL is based on the pathologic evaluation of involved tissue, usually an abdominal mass or some other extranodal site (eg, a jaw mass in endemic regions)  (<a class="graphic graphic_algorithm graphicRef62874" href="/z/d/graphic/62874.html" rel="external">algorithm 1</a>). Less commonly, involvement of typical extranodal sites of disease is absent and the diagnosis is made through pathologic evaluation of another tissue (eg, lymph node, lung, kidney, testicle). A discussion of tissue biopsy, including a general discussion of pathologic testing, is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Lymph node and tissue biopsy'</a>.)</p><p>Histology reveals monomorphic, medium-sized cells with basophilic cytoplasm and a high proliferation fraction with the Ki-67+ fraction approaching 100 percent. Cytogenetic analysis demonstrates a translocation involving the <em>MYC</em> gene on chromosome 8. Rearrangements involving <em>MYC</em> can usually be detected by routine cytogenetics but can also be demonstrated by fluorescence in situ hybridization (FISH) using commercially available probes.</p><p>Whether <em>MYC</em> rearrangement is essential for the diagnosis has been questioned by studies showing that up to 5 percent of tumors with features that are otherwise typical of BL lack <em>MYC</em> rearrangements [<a href="#rid32">32,36</a>]. In the 2023 World Health Organization classification of lymphoid neoplasms, diagnosis of BL in the absence of <em>MYC</em> rearrangement is disfavored, but it is permitted if there is strong immunohistochemical staining for MYC protein (typically in &gt;80 percent of cells) and other features are typical of BL [<a href="#rid3">3,37</a>].</p><p class="headingAnchor" id="H11"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for BL includes other tumors that can present as abdominal masses or facial tumors and other types of non-Hodgkin lymphoma. Among the other types of non-Hodgkin lymphoma that are the most difficult to differentiate from BL pathologically are lymphoblastic lymphoma, blastoid mantle cell lymphoma (MCL; which mimics the appearance of lymphoblastic lymphoma), diffuse large B cell lymphoma (DLBCL), and high-grade B cell lymphoma  (<a class="graphic graphic_table graphicRef62073" href="/z/d/graphic/62073.html" rel="external">table 2</a>). These are described in more detail below. </p><p>Features that exclude the diagnosis of BL include the presence of additional cytogenetic/molecular abnormalities (eg, rearrangements of <em>BCL6</em> and/or <em>BCL2</em>), Ki-67 staining in &lt;95 percent of the tumor cells, immunohistochemical positivity for BCL2, and the absence of strong immunohistochemical staining for MYC (typically in &gt;80 percent of cells), which is usually accompanied by the absence of <em>MYC</em> gene rearrangements. (See  <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"</a>.) </p><p>Other entities in the differential diagnosis depend largely upon the patient population and site of tumor:</p><p class="bulletIndent1"><span class="glyph">●</span>Intra-abdominal tumor – In children with an intra-abdominal tumor, the most common entities are Wilms' tumor and neuroblastoma; less commonly, other forms of lymphoma, leukemias with extensive extramedullary involvement, hepatic tumors, ovarian tumors, and soft tissue sarcomas may present as abdominal masses. Wilms' tumor and neuroblastoma occur more commonly in infants, whereas leukemic or lymphomatous involvement of the liver, spleen, or retroperitoneal lymph nodes occurs more commonly in older children. The differential diagnosis in adults includes both benign and malignant entities, such as colorectal cancer and ovarian cancer. (See  <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">"Presentation, diagnosis, and staging of Wilms tumor"</a> and  <a class="medical medical_review" href="/z/d/html/5187.html" rel="external">"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma"</a> and  <a class="medical medical_review" href="/z/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass"</a> and  <a class="medical medical_review" href="/z/d/html/3204.html" rel="external">"Adnexal mass: Differential diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3238.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2496.html" rel="external">"Clinical presentation, diagnosis, and staging of colorectal cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Facial tumor – The differential diagnosis of facial tumors includes sarcomas, carcinomas, nerve sheath tumors, melanoma, salivary gland tumors, and benign entities such as paragangliomas. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6848.html" rel="external">"Evaluation of a neck mass in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6857.html" rel="external">"Differential diagnosis of a neck mass"</a>.)</p><p></p><p>It is highly unusual for a patient to present without tumor in at least one of these locations. The differential diagnosis of patients with a non-abdominal, non-facial presentation is dependent on the site of involvement and associated symptoms.</p><p class="headingAnchor" id="H12"><span class="h2">Diffuse large B cell lymphoma</span><span class="headingEndMark"> — </span>Although most cases of BL are easily differentiated morphologically from DLBCL, some cases of BL have larger cells or an admixture of centroblast- or immunoblast-like cells, resulting in morphologic overlap between these two entities. These borderline cases are associated with a high degree of inter- and intraobserver variation among hematopathologists [<a href="#rid38">38</a>]. In children and HIV-positive patients, these tumors often have <em>MYC</em> translocations and behave similarly to typical BL, while in adults without HIV infection these cases more often are high-grade B cell lymphomas (often with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> gene rearrangements) that may arise from transformation of an underlying follicular lymphoma [<a href="#rid39">39</a>]. Regardless of the context, accurate diagnosis of BL versus DLBCL is essential for choosing the most appropriate therapy.</p><p class="headingAnchor" id="H922383147"><span class="h2">High-grade B cell lymphoma</span><span class="headingEndMark"> — </span>Both the World Health Organization Classification of hematolymphoid neoplasms 5<sup>th</sup> edition [<a href="#rid1">1</a>] and the International Consensus Classification of lymphoid neoplasms [<a href="#rid2">2</a>] recognize the existence of a heterogeneous group of aggressive B cell neoplasms with morphologic features that may mimic BL. Many of these tumors have rearrangements of <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> (so-called double- or triple-hit lymphomas) and have been placed in a new category, "high-grade B cell lymphoma with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> rearrangements"; rare exceptions are tumors that have these rearrangements but otherwise resemble lymphoblastic lymphoma or follicular lymphoma. Cases that have morphologic features intermediate between DLBCL and BL and lack rearrangements in <em>MYC</em>, <em>BCL2</em>, and <em>BCL6</em> are best categorized as "high-grade B cell lymphoma, not otherwise specified" [<a href="#rid3">3,37</a>]. </p><p class="headingAnchor" id="H13"><span class="h2">Lymphoblastic lymphoma</span><span class="headingEndMark"> — </span>Lymphoblastic lymphoma is another highly aggressive lymphoma that resembles BL histologically. However, in contrast with BL cells, lymphoblastic lymphoma cells tend to have irregular nuclei, clumped "salt and pepper" chromatin, small nucleoli, and scant cytoplasm. Also, lymphoblastic lymphomas express TdT, are often of T cell phenotype, and when of B cell origin fail to express surface Ig. Notably, a minor fraction of B lymphoblastic lymphomas have <em>MYC</em> translocation and are distinguished from BL based on expression of TdT and absence of surface Ig. Both flow cytometry and immunohistochemistry play important roles in distinguishing B cell lymphoblastic lymphoma from BL. (See  <a class="medical medical_review" href="/z/d/html/15773.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4686.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Mantle cell lymphoma, blastoid variant</span><span class="headingEndMark"> — </span>MCL is a lymphoma of adults and does not enter into the differential in children. However, cases of the blastoid variant of MCL may resemble BL morphologically. The blastoid variant of MCL is comprised of intermediate-sized cells with dispersed chromatin, irregular nuclear contours, and scant cytoplasm with a high mitotic rate. MCL can usually be distinguished from BL by its immunophenotype. While both entities express surface IgM and B cell-associated antigens, most cases of MCL express CD5 and do not express CD10 (unlike BL). In addition, nuclear staining for cyclin D1 is present in 95 percent of cases of MCL and is absent in BL. (See  <a class="medical medical_review" href="/z/d/html/4702.html" rel="external">"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis"</a>.)</p><p class="headingAnchor" id="H277459460"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117911.html" rel="external">"Society guideline links: Lymphoma diagnosis and staging"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122017.html" rel="external">"Society guideline links: Management of Burkitt lymphoma"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Burkitt lymphoma (BL) is a highly aggressive B cell neoplasm that can present in one of three distinct clinical forms: endemic, sporadic, and immunodeficiency associated. Although they are histologically identical and have similar clinical behavior, there are differences in epidemiology, clinical presentation, and genetic features between the three forms. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – BL comprises 30 percent of nonendemic pediatric lymphomas but &lt;1 percent of adult non-Hodgkin lymphomas (NHL). The endemic variant is found in equatorial Africa, while the sporadic variant is seen in the United States and Western Europe. Both endemic and sporadic BLs are most common in children, and most patients are male. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – Patients with BL present with rapidly growing tumor masses and often have evidence of tumor lysis. The endemic form presents as a jaw or facial bone tumor  (<a class="graphic graphic_picture graphicRef52625" href="/z/d/graphic/52625.html" rel="external">picture 1</a>) that spreads to extranodal sites while the nonendemic (sporadic) form has an abdominal presentation  (<a class="graphic graphic_picture graphicRef69159" href="/z/d/graphic/69159.html" rel="external">picture 2</a>), most often with massive disease. Immunodeficiency-related cases more often involve lymph nodes. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Morphology</strong> – BL tumor cells are monomorphic, medium-sized cells with round nuclei, multiple nucleoli, and basophilic cytoplasm  (<a class="graphic graphic_picture graphicRef57366" href="/z/d/graphic/57366.html" rel="external">picture 6</a>). Prominent cytoplasmic lipid vacuoles are usually evident on imprints or smears. There is an extremely high rate of proliferation, as well as a high rate of apoptotic cell death as evidenced by a Ki-67+ (MIB-1+) cells fraction approaching 100 percent and a "starry-sky" pattern. (See <a class="local">'Morphology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunophenotype</strong> – BL cells express surface IgM and B cell-associated antigens (CD19, CD20, CD22, CD79a), as well as CD10, HLA-DR, and CD43. They lack CD5, BCL2, TdT, and typically lack CD23. (See <a class="local">'Immunophenotype'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Genetic features</strong> – BL is strongly (but not uniformly) associated with a translocation among the long arm of chromosome 8, the site of the <em>MYC</em> oncogene (8q24), and one of three locations on Ig genes: t(8;14), t(2;8), or t(8;22). All cases show overexpression of MYC protein. (See <a class="local">'Genetic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Diagnosis requires a biopsy of involved tissue, which demonstrates characteristic morphology, immunophenotype, and genetic features. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis for BL includes other tumors that can present as abdominal masses and other types of NHL, including lymphoblastic lymphoma, the blastic variant of mantle cell lymphoma, diffuse large B cell lymphoma, and high-grade B cell lymphoma  (<a class="graphic graphic_table graphicRef62073" href="/z/d/graphic/62073.html" rel="external">table 2</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li class="breakAll">World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a class="nounderline abstract_t">Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol 2012; 156:744.</a></li><li><a class="nounderline abstract_t">Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer 2008; 123:2658.</a></li><li><a class="nounderline abstract_t">Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.</a></li><li><a class="nounderline abstract_t">Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.</a></li><li><a class="nounderline abstract_t">Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.</a></li><li><a class="nounderline abstract_t">Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.</a></li><li><a class="nounderline abstract_t">Boerma EG, van Imhoff GW, Appel IM, et al. Gender and age-related differences in Burkitt lymphoma--epidemiological and clinical data from The Netherlands. Eur J Cancer 2004; 40:2781.</a></li><li><a class="nounderline abstract_t">Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.</a></li><li><a class="nounderline abstract_t">Guech-Ongey M, Simard EP, Anderson WF, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 2010; 116:5600.</a></li><li><a class="nounderline abstract_t">Qian J, Wang Q, Dose M, et al. B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. Cell 2014; 159:1524.</a></li><li><a class="nounderline abstract_t">Meng FL, Du Z, Federation A, et al. Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. Cell 2014; 159:1538.</a></li><li><a class="nounderline abstract_t">Robbiani DF, Deroubaix S, Feldhahn N, et al. Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma. Cell 2015; 162:727.</a></li><li><a class="nounderline abstract_t">Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004; 104:3009.</a></li><li><a class="nounderline abstract_t">Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982; 79:7824.</a></li><li><a class="nounderline abstract_t">Pelicci PG, Knowles DM 2nd, Magrath I, Dalla-Favera R. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1986; 83:2984.</a></li><li><a class="nounderline abstract_t">Lenoir GM, Preud'homme JL, Bernheim A, Berger R. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma. Nature 1982; 298:474.</a></li><li><a class="nounderline abstract_t">Kaiser-McCaw B, Epstein AL, Kaplan HS, Hecht F. Chromosome 14 translocation in African and North American Burkitt's lymphoma;. Int J Cancer 1977; 19:482.</a></li><li><a class="nounderline abstract_t">Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18:3707.</a></li><li><a class="nounderline abstract_t">Haralambieva E, Banham AH, Bastard C, et al. Detection by the fluorescence in situ hybridization technique of MYC translocations in paraffin-embedded lymphoma biopsy samples. Br J Haematol 2003; 121:49.</a></li><li><a class="nounderline abstract_t">Neri A, Barriga F, Knowles DM, et al. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1988; 85:2748.</a></li><li><a class="nounderline abstract_t">Thomas N, Dreval K, Gerhard DS, et al. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood 2023; 141:904.</a></li><li><a class="nounderline abstract_t">Carroll WL, Yu M, Link MP, Korsmeyer SJ. Absence of Ig V region gene somatic hypermutation in advanced Burkitt's lymphoma. J Immunol 1989; 143:692.</a></li><li><a class="nounderline abstract_t">Klein U, Klein G, Ehlin-Henriksson B, et al. Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes. Mol Med 1995; 1:495.</a></li><li><a class="nounderline abstract_t">Chapman CJ, Mockridge CI, Rowe M, et al. Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intraclonal heterogeneity. Blood 1995; 85:2176.</a></li><li><a class="nounderline abstract_t">Chapman CJ, Zhou JX, Gregory C, et al. VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection. Blood 1996; 88:3562.</a></li><li><a class="nounderline abstract_t">Capello D, Carbone A, Pastore C, et al. Point mutations of the BCL-6 gene in Burkitt's lymphoma. Br J Haematol 1997; 99:168.</a></li><li><a class="nounderline abstract_t">Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, et al. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol 1991; 138:149.</a></li><li><a class="nounderline abstract_t">Onciu M, Schlette E, Zhou Y, et al. Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer 2006; 107:1084.</a></li><li><a class="nounderline abstract_t">Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354:2419.</a></li><li><a class="nounderline abstract_t">Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354:2431.</a></li><li><a class="nounderline abstract_t">Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123:1214.</a></li><li><a class="nounderline abstract_t">Schmitz R, Ceribelli M, Pittaluga S, et al. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 2014; 4.</a></li><li><a class="nounderline abstract_t">Haralambieva E, Schuuring E, Rosati S, et al. Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. Genes Chromosomes Cancer 2004; 40:10.</a></li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909.</a></li><li><a class="nounderline abstract_t">Yano T, van Krieken JH, Magrath IT, et al. Histogenetic correlations between subcategories of small noncleaved cell lymphomas. Blood 1992; 79:1282.</a></li></ol></div><div id="topicVersionRevision">Topic 4700 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22260300" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology: clues to the pathogenesis of Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18767045" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150940" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664057" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704731" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23086753" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15571961" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gender and age-related differences in Burkitt lymphoma--epidemiological and clinical data from The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045184" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813897" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25483777" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25483776" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26276629" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265787" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Adult Burkitt leukemia and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6961453" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3458257" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6806672" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/844916" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chromosome 14 translocation in African and North American Burkitt's lymphoma;.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054444" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Molecular biology of Burkitt's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12670331" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Detection by the fluorescence in situ hybridization technique of MYC translocations in paraffin-embedded lymphoma biopsy samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2833750" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36201743" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2500485" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Absence of Ig V region gene somatic hypermutation in advanced Burkitt's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8529116" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7718888" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intraclonal heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8896424" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9359519" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Point mutations of the BCL-6 gene in Burkitt's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846263" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16862570" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760442" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760443" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Molecular diagnosis of Burkitt's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24398326" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24492847" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Oncogenic mechanisms in Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034863" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9166827" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1311213" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Histogenetic correlations between subcategories of small noncleaved cell lymphomas.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
